| Metric | Value (₹ Cr) | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue | 86.68 | 12.8% | 62.1% |
| Total Income | 89.58 | 16.1% | 67.0% |
| Expenditure | 70.11 | 20.2% | 52.3% |
| PBT | 19.47 | 3.5% | 155.4% |
| Net Profit | 15.06 | 7.5% | 169.6% |
| OPM | 80.94% | 2.33pp | 16.36pp |
| NPM | 16.81% | 1.35pp | 6.39pp |
| EPS | 0.76 | 7.0% | 130.3% |
170% PAT growth masks a tightening H2 path to full-year guidance
Mufin delivered a sharp 170% PAT jump and a bullish strategic pivot to digital lending. But its full-year guidance now hinges on an H2 acceleration the call didn't justify — the real debate is whether this quarter's momentum will persist.
On the headline, Mufin's Q2 profit is a standout: PAT at ₹15.1 Cr is up 170% year-over-year and the company has swung hard to profitable digital lending, with net profit margin at 16.8%. Revenue growth of 62% confirms strong origination momentum. For a quarter alone, this is unambiguously bullish. But the story shifts when you place H1 numbers (₹29.1 Cr PAT year-to-date) against full-year guidance of ₹80–90 Cr. At the current run rate, Mufin needs to generate ₹51–61 Cr in H2—a 1.75–2.1x jump from Q2's organic pace—to stay on track. The company did not restate or narrow this guidance on the call, and offered no concrete mechanism for the acceleration. That gap, between reported momentum and guidance tightness, is the quarter's real tension.
₹15.1 Cr
+170% YoY; +7.5% QoQ
₹29.1 Cr
32–36% of FY27 target (₹80–90 Cr)
₹51–61 Cr
1.75–2.1x required growth
Profitability quality: cost discipline delivered
The profit jump is not a one-time item or accounting pop—it's anchored in real cost reduction and operating leverage. Interest expense spiked 103.7% year-over-year (driven by an EMI liability holding), but interest income outpaced it at 80.2% growth, and net interest income still climbed 52.4%. More tellingly, the company reduced its cost of borrowing to 11.17% from 13.80%, a 265 basis-point win that translates directly to margin expansion. This is structural, not cyclical. Operating leverage is real: PAT growth of 169.5% outran OpEx growth of 27.7%. Mufin's move to digital lending and away from climate financing—a topic management had euphemistically called a 'mistake'—has freed capital and discipline that now flows to the bottom line.
Claims on the call vs. what holds up
AUM tracking ₹2,500 Cr FY27 target
SupportedH1 at ₹1,766 Cr is 70.6% of target; requires ~11% H2 growth for flat YoY H2 (achievable on current origination pace)
FY27 PAT guidance ₹80–90 Cr on track
OverstatedH1 ₹29.1 Cr is 32–36% of target; Q2 grew 7.5% QoQ, far below the 1.75–2.1x pace needed in H2
Borrowing costs reduced to 11.17% from 13.80%
Supported265 basis-point reduction confirmed; achieved via PSU bank onboarding (State Bank, IOB, Union, IDBI) alongside existing funders
NPA improved sharply, gross 1.91%→1.77%, net 1.63%→1.50%
SupportedImprovement confirmed; of ₹30 Cr total NPA, ₹29 Cr is legacy EV (99%, already provisioned), ₹1 Cr from new products
Digital lending now 44% of AUM
SupportedMediclaim ₹687 Cr (38.9%), Salary Saathi ₹91 Cr (5.1%); combined ₹778 Cr on ₹1,766 Cr AUM base
What changed on this call
Mufin's business mix has undergone a sharp pivot. Climate financing, which the company had bet on for years, is now a retreating legacy book of ₹160–180 Cr (down from prior focus). That ₹25 Cr pain remaining in vehicle and battery loans is expected to stabilize; the 99% of NPA that is legacy EV portfolio is already reserved for. In its place, digital lending has surged to 44% of AUM, anchored on two products: Mediclaim (insurance premium financing, ₹687 Cr, the market's clear leader despite 50+ rivals) and Salary Saathi (government employee personal loans, ₹91 Cr, launched February 2026 and gaining traction rapidly). Arthum, a 20% equity stake in a workforce financing platform that uses a PPI wallet model, is nascent but positioned in a structural opportunity (₹20–30k Cr p.a. market, only 4 PPI licence holders in India).
On the regulatory front, Mufin was approved for an RBI AD-II (Authorised Dealer Category II) licence—a forex dealer slot—just 2 days before the earnings call. The route was unusual (direct application, not the standard FFMC ladder), which management read as regulatory confidence. Revenue impact is deferred to FY28, but the approval signals a widening product funnel.
On infrastructure, the company has upgraded visibly: hired senior CISOs (Harish Arora from Ambit, Amit Sharma from SBI Cards), migrated servers to AWS, deployed SentinelOne, and committed to quarterly VAPT audits. The Middle Layer NBFC compliance move (new RBI rules for entities at Mufin's scale) will add modest compliance capex, but management is ahead of the curve.
The bull-bear ledger
Profitability inflection is real: 170% PAT growth, 16.8% NPM, cost of borrowing down 265 bps
Strategic pivot to digital lending + Arthum workforce financing addresses structural markets
NPA quality improving (1.77% gross), legacy climate book shrinking, new-product NPA isolated (₹1 Cr)
AUM trajectory on pace for ₹2,500 Cr FY27 target (70.6% by H1); origination momentum strong
FY27 PAT guidance of ₹80–90 Cr now requires 1.75–2.1x H2 growth vs 7.5% QoQ current pace; no H2 narrowing or roadmap on call
Mediclaim market now has 50+ competitors; product margins under pressure despite claimed market share and service edge
Climate tail ₹25 Cr pain could slip if EV market deteriorates; retention risk on junior team scaling
FY28 guidance vague ('golden period'); Arthum and new products early-stage; execution risk on new verticals
Risks, ranked by how much they should concern a holder
PAT guidance path tightens in H2
HighH1 is only 36% of FY27 target (₹80–90 Cr); Q2 grew 7.5% QoQ, far below the 1.75–2.1x needed. If H2 disappoints, full-year miss and credibility dent; stock reprices lower.
Mediclaim market commoditization
Medium50+ competitors replicating Mediclaim; product margin erosion expected. Mufin claims market size (20–25% p.a. growth) can support all players, but yields under pressure. ₹687 Cr (38.9% of AUM) is concentrated; repricing risk.
Cyber security as platform scales
Medium5–10 minute digital onboarding attracts hacker attention. Mufin recently hired CISOs and upgraded to AWS + SentinelOne, but infrastructure risk elevated as they scale digital. Breach or regulatory penalty could spike OpEx or dent brand.
Climate financing tail slippage
Low₹25 Cr pain remaining in ₹160–180 Cr book. If EV market deteriorates, slippage could exceed expectations. Mitigated by 99% of NPA being legacy (already provisioned) and EV book shrinking.
Arthum and new products execution
LowArthum (workforce financing) early-stage; market large (₹20–30k Cr p.a.) but only 4 PPI licence holders. Execution on insurance partner integration, unit economics, and scale unproven. FY28 is claimed 'golden period' but no quantified guidance.
How the street is positioned
Mufin's stock is trading at ₹139.27 as of November 17, 2026, in a bullish trend (above SMA20 at ₹136.44, SMA50 at ₹135.13, SMA200 at ₹124.07). The 52-week range is ₹95–₹145; at the all-time high of ₹274.4, the stock has fallen 49.25%—a sharp drawdown, but the current price sits 46.6% above the 52-week low, suggesting the market is pricing in a recovery narrative. RSI is neutral at 54.7, volume normal.
Institutional ownership tells a nuanced story. FII have trimmed from 2.26% in Q1 FY27 to 1.80% in Q2 (−46 bps), signalling caution or profit-taking. DII remain flat at 10.05%. Promoter stake is stable at 47.30%, showing no dilution concerns from management's view. Recent bulk/block deals in early November (Nivesh Consultancy bought ₹833k shares at ₹135.59, then sold ₹1,085k at ₹134.10; Three Words Capital sold ₹1,090k at ₹131.51; Aakanksha Satyen Mamtora bought ₹1,120k at ₹131.59) show mixed conviction—no promoter or insider-linked selling near the highs, but tactical trading around ₹131–135. The absence of concerning insider selling near the ATH is reassuring.
The market's own verdict on the print is mixed. A 49% drawdown from ATH, combined with a 46% recovery off lows, suggests the street is in debate—the fundamental case for profitability and digital pivot is accepted, but the guidance path is questioned. The FII exit, modest in magnitude but directional, hints that overseas investors are waiting for clarity on H2 momentum before re-entering. The current price is a reasonable entry point for holders willing to weather H2 execution risk; it is not a screaming bargain.
The debate
The honest read: Mufin has delivered a credible Q2 and a bullish strategic pivot. Profitability quality is high and cost discipline is durable. But the company's full-year guidance now hinges on an H2 acceleration that the call did not justify. Management is confident ('on track', 'no issue') but offered no mechanism for the 1.75x jump needed. The debate is real: Can Mufin sustain momentum (and accelerate) into H2, or does Q2 mark a peak and guidance gets revised lower? The stock's current price (46% recovery, still -49% from ATH) reflects this honest uncertainty. For holders, the Q3 print will resolve the debate—if Q3 PAT grows 15%+ QoQ, the H2 path opens up and the bull case compounds. If Q3 grows 5–10% QoQ, the guidance miss becomes likely and re-rating down is warranted.
What to watch next
1 · Q3 PAT inflection (critical)
The make-or-break metric. If Q3 PAT grows 15%+ QoQ from Q2's ₹15.1 Cr, momentum is real and the ₹80–90 Cr FY27 target is back on table. If Q3 grows 5–10% QoQ, the H2 path breaks and a guidance miss becomes likely. This is the pivot point.
2 · Disbursement run rate and digital AUM mix
Q2 disbursements were ₹590 Cr (+31% QoQ). Watch Q3–Q4 for sustained 20%+ QoQ growth and whether digital products (Mediclaim, Salary Saathi, Arthum) are maintaining yields under 50+ competitor pressure. Pricing erosion in Mediclaim would signal margin headwind.
3 · RBI Middle Layer NBFC compliance capex and Arthum scaling
Infrastructure investments (AWS, SentinelOne, vendor onboarding) are rising. Watch Q3–Q4 for OpEx growth outpacing revenue—if compliance capex spikes faster than margins expand, leverage gain stalls. Separately, Arthum's insurance partner integration and unit economics are worth tracking; early performance will signal whether the ₹20–30k Cr workforce financing market is as addressable as management claims.
Mufin Green Finance delivered a strong Q2—profitability inflected sharply, borrowing costs fell 265 bps, and the company has credibly pivoted to digital lending in structural markets. But the quarter is not a step-change; it is a proof-of-concept on a tightening timeline. Full-year PAT guidance of ₹80–90 Cr now rests on an H2 acceleration that management did not justify on the call, and the stock's 49% drawdown from its all-time high reflects this real execution risk. For holders, this is a Hold: the bull case is intact (cost discipline, digital mix, NPA improving, AUM on track), but the near-term bar is high. The single number to track from here is Q3 PAT growth—if it inflects 15%+ QoQ, the momentum compounds and a re-rating higher is earned. If Q3 grows slower, a guidance miss and downside repricing follow. The street has priced in debate; the next quarter resolves it.
Strong profitability surge, but PAT guidance path tightens in H2
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 7/10
Grade B
FY27 AUM target (₹2,500 Cr) on track at 70.6% by H1; PAT guidance path tight—may miss without H2 acceleration.
Optimistic
next 1–2 quarters
Optimistic
multi-year
Mufin delivered strong Q2 (PAT +170% YoY, revenue +62%), pivoted to profitable digital lending, and reduced borrowing costs to 11.17%. However, FY27 PAT guidance of ₹80–90 Cr now requires ₹51–61 Cr in H2 versus H1's ₹29.1 Cr—a 1.75–2.1x jump unlikely at current 7.5% QoQ growth rates. Execution risk and tightening guidance path warrant Hold over Buy.
₹86.7 Cr
Revenue · +62.1% YoY₹15.1 Cr
Reported PAT · +169.5% YoYExpanding
Margins · vs guidance: MixedDid the claims hold up?
AUM tracking ₹2,500 Cr FY27 target, now at ₹1,766 Cr
METH1 ₹1,766 Cr is 70.6% of ₹2,500 Cr target; on pace if H2 grows ~11%, slightly ahead for flat YoY H2
FY27 PAT target ₹80–90 Cr on track
OVERSTATEDH1 ₹29.1 Cr is 32–36% of target; requires 51–61 Cr in H2 (1.75–2.1x H1), vs Q2 7.5% QoQ growth
Cost of borrowing reduced to 11.17% from 13.80%
METBorrowing costs fell 265 bps; enabled by onboarding PSU/large banks alongside existing funders
NPA improved sharply, gross 1.91%→1.77%, net 1.63%→1.50%
METNPA improvement confirmed; ₹30 Cr total, ₹29 Cr from EV retail legacy (99%), ₹1 Cr from new products
Digital lending now 44% of AUM, two products (Mediclaim ₹687 Cr, Salary Saathi ₹91 Cr)
METMediclaim 38.9% of AUM, Salary Saathi 5.1%; combined ₹778 Cr. Market position: Mediclaim 50+ competitors but Mufin claims market share and 20–25% annual growth
Earnings quality
What changed since the last call
Pivoted climate financing to digital-first
UpgradeClimate focus now zero (prior: material); climate book ₹160–180 Cr shrinking. Digital lending now 44% of AUM (Mediclaim ₹687 Cr, Salary Saathi ₹91 Cr), vs ~20% in FY26.
Cost of borrowing fell 265 bps
UpgradeReduced from 13.80% to 11.17% via PSU bank onboarding. Enables margin expansion; debt-to-equity at 2.89x (up from 2.43x) but lenders comfortable within ~4x limit.
NPA quality improved; legacy EV tail shrinking
UpgradeGross NPA 1.91%→1.77%, Net NPA 1.63%→1.50%. Of ₹30 Cr NPA, ₹29 Cr is legacy EV (99%), ₹1 Cr from new products. EV book performing well post-pivot.
AD-II license approved (not yet disclosed)
NewRegulatory win: Mufin applied directly for AD-II (forex dealer), unusual route. Plans new lending products; competitors mostly unsecured. Demonstrates RBI confidence but no revenue impact yet.
No H2 PAT guidance restatement
NeutralFY27 PAT ₹80–90 Cr target maintained verbally, but no explicit H2 narrowing. FY28 called "golden period" (vague). Suggests some caution on H2 certainty.
The Q&A
Investors (Karan Gala, Sandeep Kapadia) pressed hard on climate financing pain, NPA composition, AUM capacity, tech security, competitive moat, and AI adoption. Management held up well; answered most directly. Some hedging: AUM ceiling ₹3–3.5 Cr by FY27–28 (timeline withheld), AI roadmap deferred. Overall tone: confident on model, cautious on specifics.
Climate financing pain — Karan Gala, investor
AnsweredClimate focus zero. ₹100–110 Cr vehicle loans + ₹60–70 Cr battery loans remain; ₹25 Cr pain left in books. Rest of book (cars, buses) expected no major slippage.
NPA composition — Karan Gala, investor
AnsweredEV book: 99% NPA is legacy (already provisioned). Total NPA ~₹30 Cr; ₹29 Cr from EV retail, ₹1 Cr from new products. Recovery possible on new-product NPA.
AUM capacity & capital need — Karan Gala, investor
PartialNo fresh capital needed until ₹3,000–3,500 Cr AUM. Ambitious on FY27–28 targets but won't share numbers. Profit growth + lower costs will add capital. Dilution unacceptable; capital not a constraint.
Technology & security — Sandeep Kapadia, investor
AnsweredHired senior security personnel (Harish Arora from Ambit, Amit Sharma from SBI Cards). Migrated servers to AWS. Deployed SentinelOne for external breach blocking. Quarterly VAPT audits. Compliant with RBI Middle Layer NBFC rules; onboarding top-tier third-party vendors.
Competitive edge & moat — Sandeep Kapadia, investor
AnsweredProducts (Mediclaim, Arthum) differ in moat. Mediclaim: became commodity after 50 players entered; edge is service + innovation. Arthum: only 4 PPI licence holders in India; took 6 months to build (others need 1–1.5 yrs). Moat is PPI licence + tech ERP player (5–6 nationwide) + NBFC combo (vault with combo lock).
AI adoption in lending — Sandeep Kapadia, investor
PartialCurrently using AI in DevOps (coding) and collections (multilingual reminder bots). Not using AI for underwriting; focus on secured lending where collections largely secured. Team exploring underwriting AI but not priority yet. Will track future initiatives.
R&D and infrastructure tracking — Sandeep Kapadia, investor
AnsweredAgreed. KPIs should track four pillars: secured vs unsecured, scaling each segment, tech enablement, profitability via cost-of-capital reduction. These metrics should frame R&D and infrastructure spend.
Guidance
FY27 target implicit ~₹340–360 Cr (derived from ₹2,500 Cr AUM)
MediumH1 revenue ₹163.6 Cr (₹76.9+₹86.7); needs H2 ~₹176–196 Cr (8–20% growth). Current trajectory sustainable if Q3–Q4 average mid-₹85–₹90s Cr.
FY27 PAT target ₹80–90 Cr (NPM target ~22–25% on ₹340–360 Cr revenue)
LowH1 PAT ₹29.1 Cr (₹14+₹15.1); needs H2 ₹51–61 Cr. Q2 grew 7.5% QoQ; H2 needs 1.75–2.1x pace. No H2 guidance narrowing given.
Infrastructure investment rising to support Middle Layer NBFC compliance
MediumTech hiring (security CISOs), AWS migration, SentinelOne deployment, quarterly VAPT audits. OpEx expected to rise modestly; economies of scale to offset by FY28.
Risks the call surfaced
Execution on PAT guidance
HighH1 PAT ₹29.1 Cr is 32–36% of ₹80–90 Cr FY27 target; Q2 growth was 7.5% QoQ, far below the 1.75–2.1x needed in H2. No H2 guidance narrowing suggests management may accept shortfall.
Climate financing tail
Low₹160–180 Cr climate book shrinking; ₹100–110 Cr vehicle loans + ₹60–70 Cr battery loans. ₹25 Cr pain remaining; legacy EV account for 99% of ₹30 Cr total NPA. Expected "no major slippage", but EV market downturn could surprise.
Competition in digital lending
MediumMediclaim financing market now has 50+ players (vs 1–2 at launch). Mufin claims market size (~20–25% annual growth) can support all players, but yields under pressure. Salary Saathi and Arthum also face competitive replication risk. Mufin's edge claimed as service + innovation, but financial products become commodities.
Cyber security & data risk
MediumDigital lending platform (5–10 minute onboarding) attracts hacker attention; Mufin scaling tech infrastructure. Recently hired senior security CISOs (Harish Arora from Ambit, Amit Sharma from SBI), migrated to AWS, deployed SentinelOne, quarterly VAPT audits. Early mitigations in place, but risk elevated as they scale.
Regulatory transition to Middle Layer NBFC
LowMufin recently moved to Middle Layer NBFC (RBI scale-based regulation). New rules impose infrastructure, audit, and vendor onboarding requirements. OpEx expected to rise modestly; economies of scale to offset by FY28.
Management
Score 7/10. Clear on financials and business model; transparent on challenges (climate losses, NPA, competition). Some caution on specifics (AUM ceiling stated but timeline withheld, AI roadmap deferred). Honest on past mistakes (Blue Smart ₹15–20 Cr loss, climate 3-year 'mistake'). Delivered Q2 results on track: PAT +169.5% YoY, revenue +62.1% YoY, AUM target 70.6% by H1, borrowing costs down 265 bps. FY27 PAT guidance at risk (H1 is 36% of target, needs acceleration). Overall execution solid on profitability, tight on growth guidance.
1 · Q3 FY27
Early test of H2 momentum needed to track ₹80–90 Cr PAT; Arthum scaling begins
2 · Q4 FY27
Full-year PAT result; validate ₹2,500 Cr AUM target hit; AD-II license buildout timeline
3 · FY28
Management promised "golden period"; new products (impact lending, Arthum workforce) expected to scale
Execution risk and tightening guidance path warrant Hold over Buy.